

COMBINED DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled SPECIFIC INHIBITORS OF NFAT ACTIVATION BY CALCINEURIN AND THEIR USE IN TREATING IMMUNE-RELATED DISEASES, the specification of which

- ☐ is attached hereto.
☒ was filed on February 11, 1999 as Application Serial No. 09/248,620 and was amended on _____
☐ was described and claimed in PCT International Application No. _____
filed on _____ and as amended under PCT Article 19 on _____.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose all information I know to be material to patentability in accordance with Title 37, Code of Federal Regulations, §1.56.

I hereby appoint the following attorneys and/or agents to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith: P. Louis Myers (Reg. No. 35,965), Timothy A. French (Reg. No. 30,175).

Address all telephone calls to P. Louis Myers at telephone number 617/542-5070.

Address all correspondence to P. Louis Myers, Fish & Richardson P.C., 225 Franklin Street, Boston, MA 02110-2804.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patents issued thereon.

Full Name of Inventor: Patrick G. Hogan

Inventor's Signature: Patrick G. Hogan

Date: 15 JUN 99

Residence Address: 19 Agassiz Street #31, Cambridge, MA 02140

Citizen of: United States

Post Office Address: same as above

Full Name of Inventor: Anjana Rao

Inventor's Signature: Anjana Rao

Date: 15 June 1999

Residence Address: 19 Agassiz Street #31, Cambridge, MA 02140

COMBINED DECLARATION AND POWER OF ATTORNEY CONTINUED

Citizen of: United States

Post Office Address: same as above

Full Name of Inventor: Jose Aramburu

Inventor's Signature:  Date: 15 June 1999

Residence Address: 368 Longwood Avenue, Apt. 45, Boston, MA 02215

Citizen of: Spain

Post Office Address: same as above

DECLARATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Patrick G. Hogan, Anjana Rao and Jose Aramburu

SERIAL NO. Not Assigned

FILED: Herewith

ENTITLED: SPECIFIC INHIBITORS OF NFAT ACTIVATION BY CALCINEURIN AND THEIR
USE IN TREATING IMMUNE-RELATED DISEASES

VERIFIED STATEMENT CLAIMING SMALL ENTITY STATUS
(37 C.F.R. § 1.9(f) and § 1.27(d)) - NONPROFIT ORGANIZATION

Assistant Commissioner for Patents
Washington, D.C. 20231

THE UNDERSIGNED DECLARE(S):

Exclusive rights in the above-identified invention reside in the "small entity(ies)" defined and named below, and "small entity" fees are appropriate. Qualification as a small entity is based upon the appropriately checked statements below:

☒ **INDEPENDENT INVENTOR(S)**

The below-signing independent inventor(s) has (have) not assigned, granted, conveyed or licensed, and is (are) under no obligation under contract or law to assign, grant, convey or license any rights in the invention to any person who could not likewise be classified as an independent inventor under 37 C.F.R. 1.9(c) if that person had made the invention, or to any concern which would not qualify as a small business concern under 37 C.F.R. § 1.9(d) or a nonprofit organization under 37 C.F.R. § 1.9(e).

☐ **SMALL BUSINESS CONCERN**

The below-identified small business concern qualifies as a small business as defined in 13 C.F.R. § 121.3-18, and reproduced in 37 C.F.R. § 1.9(d), for purposes of paying reduced fees under Sections 41(a) and (b) of Title 35, in that the number of employees, including those of its affiliates, which does not exceed 500 persons, and it has not assigned, granted, conveyed or licensed, and is under no obligation under contract or law to assign, grant, convey or license, any rights in the invention to any person who could not be classified as an independent inventor if that person had made the invention, or to any concern which would not qualify as a small business concern under 37 C.F.R. § 1.9(d) or a nonprofit organization under 37 C.F.R. § 1.9(e).

Concerns are affiliates of each other when, either directly or indirectly, one concern controls or has the power to control the other, or a third party controls or has the power to control both. The number of employees of the business concern is the average over the fiscal year of the persons employed during each of the pay periods of the fiscal year. Employees are those persons employed on a full-time, part-time or temporary basis during the previous fiscal year of the concern.

[X] NONPROFIT ORGANIZATION (Check additional applicable box)

The below-identified nonprofit organization qualifies as a small entity under 37 C.F.R. § 1.9(e) in that it constitutes:

1. ☐ a university or other institution of higher education located in any country; or
2. ☒ an organization of the type described in Section 501(c)(3) of the Internal Revenue Code of 1954 (26 U.S.C. § 501(c)(3)) and exempt from taxation under Section 501(a) of the Internal Revenue Code (26 U.S.C. § 501(a)); or
3. ☐ any nonprofit scientific or educational organization qualified under a nonprofit organization statute of a state of the United States (35 U.S.C. § 201(i)); or
4. ☐ any nonprofit organization located in a foreign country which would qualify as a nonprofit organization under paragraphs (e)(2) or (3) of Rule 1.9 if it were located in the United States.

The undersigned acknowledge(s) the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate (37 C.F.R. § 11.28(b)).

The below-signing individual(s) hereby declare(s) that (he, she, they) are authorized to execute this statement on behalf of the small entity; that all statements made herein of (his, her, their) own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issue thereon, or any patent to which this verified statement is directed.

Name of Small Entity: (Independent Inventor/Small Business/Nonprofit)

The Center for Blood Research, Inc.

Address of Small Entity: (Street, City, State or Country, Zip Code)

800 Huntington Avenue, Boston, MA 02115

Name of Person Signing: (Small Business/Nonprofit)

William McCormick

Title of Person Signing: (Small Business/Nonprofit)

Vice President for Scientific and Regulatory Affairs

Signature: (Please sign and date in permanent ink.)

Date signed:

x William McCormick

x Jan. 29, 1999